Literature DB >> 20664267

Prevention of stroke in patients with atrial fibrillation: the role of new antiarrhythmic and antithrombotic drugs.

Joachim Röther1, Harry Crijns.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is associated with increased cardiovascular mortality and morbidity, including stroke.
RESULTS: Rate or rhythm control and prevention of thromboembolism with oral anticoagulants are the main management objectives for patients with AF. Until recently, rhythm control studies did not show prevention of cardiovascular complications. However, dronedarone, a novel antiarrhythmic drug, has been shown to decrease stroke risk by 34% (p = 0.027). In addition, the Randomized Evaluation of Long-Term Anticoagulant Therapy trial showed significant stroke reductions with the anticoagulant dabigatran 150 mg b.i.d. compared with adjusted-dose warfarin (the results for dabigatran 110 mg b.i.d. were similar to warfarin).
CONCLUSIONS: Novel antithrombotic agents and antiarrhythmic agents with cardiovascular prophylactic properties may enhance the management of stroke risk in patients with AF. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20664267     DOI: 10.1159/000319608

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  2 in total

1.  Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study.

Authors:  Pei-Chun Chen; Gregory Y H Lip; Grace Yeh; Hung-Ju Lin; Kuo-Liong Chien
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

2.  Human Urinary Kallidinogenase decreases recurrence risk and promotes good recovery.

Authors:  Dong Han; Xin Chen; Dongmei Li; Shuang Liu; Yi Lyu; Juan Feng
Journal:  Brain Behav       Date:  2018-07-20       Impact factor: 2.708

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.